4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we’ve learned so far

Latest Allergy & Immunology Articles

• As-Needed Albuterol–Budesonide in Mild Asthma May 19, 2025
  In a randomized trial, as-needed albuterol–budesonide resulted in a lower risk of severe asthma exacerbation than as-needed albuterol among participants with disease that was uncontrolled despite treatment for mild asthma.
  Craig LaForce, Frank Albers, Anna Danilewicz, Allison Jeynes-Ellis, Monica Kraft, Reynold A. Panettieri Jr., Robert Rees, Samuel Bardsley, Lynn Dunsire, Tim Harrison, Olami Sobande, Raulin Surujbally, Frank Trudo, Christy Cappelletti, Alberto Papi, Richard Beasley, Bradley E. Chipps, Elliot Israel, Hitesh Pandya, Martin Clancy, Leonard B. Bacharier, the BATURA Investigators*
• Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis May 15, 2025
  In this phase 3 trial involving participants with nonrelapsing secondary progressive multiple sclerosis, treatment with tolebrutinib resulted in a lower risk of disability progression than placebo.
  Robert J. Fox, Amit Bar-Or, Anthony Traboulsee, Celia Oreja-Guevara, Gavin Giovannoni, Patrick Vermersch, Sana Syed, Ye Li, Wendy S. Vargas, Timothy J. Turner, Erik Wallstroem, Daniel S. Reich, the HERCULES Trial Group*
• Progress toward Mitigating Disability Progression in Multiple Sclerosis May 15, 2025
  Multiple sclerosis is the most common cause of progressive neurologic disability in young adults. There had been no treatments for the disease, except for glucocorticoids, which were used for more than 25 years before they were shown to reduce the duration and severity of acute relapses but to have no...
  Peter A. Calabresi